Literature DB >> 30578674

Disease duration and disability in dysfeRlinopathy can be described by muscle imaging using heatmaps and random forests.

David Gómez-Andrés1, Jorge Díaz2, Francina Munell1, Ángel Sánchez-Montáñez3, Irene Pulido-Valdeolivas4, Lionel Suazo2, Cristián Garrido2, Susana Quijano-Roy5, Jorge A Bevilacqua6,7.   

Abstract

INTRODUCTION: The manner in which imaging patterns change over the disease course and with increasing disability in dysferlinopathy is not fully understood.
METHODS: Fibroadipose infiltration of 61 muscles was scored based on whole-body MRI of 33 patients with dysferlinopathy and represented in a heatmap. We trained random forests to predict disease duration, Motor Function Measure dimension 1 (MFM-D1), and modified Rankin scale (MRS) score based on muscle scoring and selected the most important muscle for predictions.
RESULTS: The heatmap delineated positive and negative fingerprints in dysferlinopathy. Disease duration was related to infiltration of infraspinatus, teres major-minor, and supraspinatus muscles. MFM-D1 decreased with higher infiltration of teres major-minor, triceps, and sartorius. MRS related to infiltration of vastus medialis, gracilis, infraspinatus, and sartorius. DISCUSSION: Dysferlinopathy shows a recognizable muscle MRI pattern. Fibroadipose infiltration in specific muscles of the thigh and the upper limb appears to be an important marker for disease progression. Muscle Nerve 59:436-444, 2019.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  disability; dysferlin; heatmap; machine learning; muscle imaging; random forest

Mesh:

Year:  2019        PMID: 30578674     DOI: 10.1002/mus.26403

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.

Authors:  Mauro Monforte; Sara Bortolani; Eleonora Torchia; Lara Cristiano; Francesco Laschena; Tommaso Tartaglione; Enzo Ricci; Giorgio Tasca
Journal:  J Neurol       Date:  2021-09-06       Impact factor: 4.849

2.  Genetic Profile of Patients with Limb-Girdle Muscle Weakness in the Chilean Population.

Authors:  Mathieu Cerino; Patricio González-Hormazábal; Mario Abaji; Sebastien Courrier; Francesca Puppo; Yves Mathieu; Alejandra Trangulao; Nicholas Earle; Claudia Castiglioni; Jorge Díaz; Mario Campero; Ricardo Hughes; Carmen Vargas; Rocío Cortés; Karin Kleinsteuber; Ignacio Acosta; J Andoni Urtizberea; Nicolas Lévy; Marc Bartoli; Martin Krahn; Lilian Jara; Pablo Caviedes; Svetlana Gorokhova; Jorge A Bevilacqua
Journal:  Genes (Basel)       Date:  2022-06-16       Impact factor: 4.141

3.  Blockade of Hemichannels Normalizes the Differentiation Fate of Myoblasts and Features of Skeletal Muscles from Dysferlin-Deficient Mice.

Authors:  Luis A Cea; Gabriela Fernández; Guisselle Arias-Bravo; Mario Castillo-Ruiz; Rosalba Escamilla; María C Brañes; Juan C Sáez
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

4.  Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy.

Authors:  Harmen Reyngoudt; Fiona E Smith; Ericky Caldas de Almeida Araújo; Ian Wilson; Roberto Fernández-Torrón; Meredith K James; Ursula R Moore; Jordi Díaz-Manera; Benjamin Marty; Noura Azzabou; Heather Gordish; Laura Rufibach; Tim Hodgson; Dorothy Wallace; Louise Ward; Jean-Marc Boisserie; Julien Le Louër; Heather Hilsden; Helen Sutherland; Aurélie Canal; Jean-Yves Hogrel; Marni Jacobs; Tanya Stojkovic; Kate Bushby; Anna Mayhew; Volker Straub; Pierre G Carlier; Andrew M Blamire
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-04-03       Impact factor: 12.063

5.  Progression to Loss of Ambulation Among Patients with Autosomal Recessive Limb-girdle Muscular Dystrophy: A Systematic Review.

Authors:  Ivana F Audhya; Antoinette Cheung; Shelagh M Szabo; Emma Flint; Conrad C Weihl; Katherine L Gooch
Journal:  J Neuromuscul Dis       Date:  2022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.